Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Stent Stories

2013-10-30 23:36:00

A national law firm representing defective medical device victims, Carey Danis & Lowe is currently investigating Bard LifeStent cases following an FDA class 1 recall. St. Louis, Missouri (PRWEB) October 30, 2013 The defective medical device attorneys at Carey Danis & Lowe are currently investigating Bard LifeStent cases following an October 18, 2013 recall announcement made by the U.S. Food and Drug Administration (FDA). As a national law firm representing victims of defective...

2013-10-30 15:34:04

New study compares 2 newer generation drug-eluting stents with biocompatible and biodegradable polymers A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible polymer stents in patients undergoing percutaneous coronary intervention (PCI). The findings of the SORT-OUT VI trial were presented today at the 25th annual...

2013-10-30 08:32:41

Financial credit provided if second stent is required in a CorPath robotic-assisted angioplasty WALTHAM, Mass., Oct. 30, 2013 /PRNewswire/ -- Corindus Vascular Robotics, a leading provider of precision medical robotics, today announced the launch of its CorPath One Stent Program. The goal of the program is to raise awareness of the potential to decrease longitudinal geographic miss (LGM) caused by sub-optimal stent placement, as well as the patient safety and financial benefits...

2013-10-29 23:28:30

As the US population ages and obesity rises, cardiovascular device markets reach billions in market value. Vancouver, BC (PRWEB) October 29, 2013 iData Research, the leading global authority in medical device and pharmaceutical market research, has published a new report series for the U.S. Cardiology Device Markets. Cardiovascular disease is much more prevalent among patients over 55 years of age; therefore as the U.S. population ages, the incidence of cardiovascular disease will...

2013-10-29 20:22:40

Data from the EGO-COMBO Study Presented at TCT 2013 SAN FRANCISCO, Oct. 29, 2013 /PRNewswire/ -- OrbusNeich today announced that new clinical data presented at TCT 2013 show durable outcomes as well as excellent early healing and optimal neointimal suppression out to 24 months following placement of the COMBO Dual Therapy Stent. These results from the EGO-COMBO Study were presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China, at the annual...

2013-10-29 20:22:14

Results of analysis of IVUS use in 8,582-patient, multicenter ADAPT-DES Study presented during oral session at 25th Annual TCT Scientific Symposium extend and confirm one-year findings SAN FRANCISCO, Oct. 29, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced new two-year outcomes from an analysis of use of...

2013-10-29 16:26:15

Company to Host Conference Call Tomorrow at 5:30 a.m. PT / 8:30 a.m. ET BOSTON, Oct. 29, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced new 12-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients....

2013-10-28 12:25:36

NATICK, Mass., Oct. 28, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful innovation to clinicians and patients through a robust schedule of sponsored research presentations at the 25(th) Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, October 27 - November 2 in San Francisco. The clinical...

2013-10-28 08:29:48

BOSTON, Oct. 28, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will host a conference call to discuss its MASTER trial 12-month follow up data on October 30, 2013 at 8:30 a.m. ET / 5:30 a.m. PT. Joining the call will be Alan Milinazzo, President and Chief Executive Officer, Craig Chore, Chief Financial Officer, and Dr. Campbell Rogers, a member of InspireMD's Board of Directors....

2013-10-28 08:28:49

- Demonstrated Lack of Late Lumen Loss Progression Over 18 Months in Conjunction with Excellent Tissue Healing - DURHAM, N.C., Oct. 28, 2013 /PRNewswire/ -- Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(®)) were presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San...


Latest Stent Reference Libraries

Interventional Radiology
2013-03-04 16:18:42

Interventional radiology (IR) is a special sub-operation under general radiology. It is used to find, diagnose and treat a disease in almost every body system. The process of interventional radiology is very noninvasive to help with the recovery and outcome of the procedure. It utilizes x-rays, CT, ultrasound, MRI, and other modes of imaging in order to direct tools in the body as well as a variety of catheters, narrow tubes, so that incisions can be minimalized. How it is Performed...

More Articles (1 articles) »